JP2007504235A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504235A5
JP2007504235A5 JP2006525396A JP2006525396A JP2007504235A5 JP 2007504235 A5 JP2007504235 A5 JP 2007504235A5 JP 2006525396 A JP2006525396 A JP 2006525396A JP 2006525396 A JP2006525396 A JP 2006525396A JP 2007504235 A5 JP2007504235 A5 JP 2007504235A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heteroarylalkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006525396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504235A (ja
JP4842817B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/028308 external-priority patent/WO2005023815A2/en
Publication of JP2007504235A publication Critical patent/JP2007504235A/ja
Publication of JP2007504235A5 publication Critical patent/JP2007504235A5/ja
Application granted granted Critical
Publication of JP4842817B2 publication Critical patent/JP4842817B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006525396A 2003-09-03 2004-08-31 神経保護二環式化合物およびその使用方法 Expired - Lifetime JP4842817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49995603P 2003-09-03 2003-09-03
US60/499,956 2003-09-03
PCT/US2004/028308 WO2005023815A2 (en) 2003-09-03 2004-08-31 Neuroprotective bicyclic compounds and methods for their use

Publications (3)

Publication Number Publication Date
JP2007504235A JP2007504235A (ja) 2007-03-01
JP2007504235A5 true JP2007504235A5 (cg-RX-API-DMAC7.html) 2007-10-04
JP4842817B2 JP4842817B2 (ja) 2011-12-21

Family

ID=34272894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525396A Expired - Lifetime JP4842817B2 (ja) 2003-09-03 2004-08-31 神経保護二環式化合物およびその使用方法

Country Status (9)

Country Link
US (2) US8067425B2 (cg-RX-API-DMAC7.html)
EP (1) EP1664050B1 (cg-RX-API-DMAC7.html)
JP (1) JP4842817B2 (cg-RX-API-DMAC7.html)
DK (1) DK1664050T3 (cg-RX-API-DMAC7.html)
ES (1) ES2564803T3 (cg-RX-API-DMAC7.html)
HU (1) HUE028528T2 (cg-RX-API-DMAC7.html)
PL (1) PL1664050T3 (cg-RX-API-DMAC7.html)
SI (1) SI1664050T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005023815A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2381775T3 (es) 2000-08-04 2012-05-31 Dmi Biosciences, Inc. Procedimiento del uso de dicetopiperazinas y composición que las contiene
US7485630B2 (en) * 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use
CN101947306B (zh) 2003-05-15 2014-06-18 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
WO2008063311A2 (en) * 2006-10-11 2008-05-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US8791117B2 (en) 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US8519127B2 (en) * 2003-09-03 2013-08-27 Mike John Bickerdike Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
JP5856843B2 (ja) * 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ,インコーポレイテッド ジケトピペラジンを用いた医薬組成物
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
KR102032400B1 (ko) 2011-10-10 2019-10-15 앰피오 파마슈티컬스 인코퍼레이티드 퇴행성 관절 질환의 치료
EP2765968A4 (en) 2011-10-10 2015-01-21 Ampio Pharmaceuticals Inc IMPLANTABLE MEDICINE PRODUCTS WITH INCREASED IMMUNO TOLERANCE AND PROCESSING AND IMPLANTATION METHODS
SG10201605205VA (en) 2011-10-28 2016-08-30 Ampio Pharmaceuticals Inc Treatment of rhinitis
CA2900335C (en) * 2012-10-22 2021-10-26 City Of Hope Synthetic analogs of epipolythiodioxopiperazines and uses thereof
KR20150132508A (ko) 2013-03-15 2015-11-25 앰피오 파마슈티컬스 인코퍼레이티드 줄기세포의 가동화, 회귀, 증식 및 분화를 위한 조성물 및 이의 사용 방법
LT3024463T (lt) * 2013-07-25 2020-07-10 Neuren Pharmaceuticals Limited Neuroapsauginiai bicikliniai junginiai ir jų panaudojimo būdai autizmo spektro sutrikimų ir neuroliginių vystymosi sutrikimų gydymui
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
CN109562110A (zh) 2016-05-26 2019-04-02 株式会社日本阿明诺化学 睡眠改善剂
CN109952104B (zh) 2016-09-15 2023-03-28 希望之城 二硫etp衍生物
WO2019177142A1 (ja) 2018-03-16 2019-09-19 脳科学香料株式会社 低酸素障害、虚血再灌流障害又は炎症の予防又は治療剤、移植用細胞保護剤、及び生体保存剤
AU2019271189A1 (en) 2018-05-15 2021-01-07 Lloyd Hung Loi TRAN Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders
JP2022553060A (ja) 2019-10-22 2022-12-21 ニューレン ファーマシューティカルズ リミテッド 二環式化合物及びピット・ホプキンス症候群の処置におけるそれらの使用方法
US20240132511A1 (en) * 2021-02-12 2024-04-25 Neuren Pharmaceuticals Limited Treatments of prader-willi syndrome
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469006A (de) * 1965-07-07 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer synthetischer Alkaloide
FI941826A7 (fi) * 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
US7202279B1 (en) * 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
CA2466701C (en) 2001-11-13 2013-11-12 Loi Tran Neuroprotective use of cyclic prolyl glycine
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US7485630B2 (en) * 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use

Similar Documents

Publication Publication Date Title
JP2007504235A5 (cg-RX-API-DMAC7.html)
JP2020169171A5 (cg-RX-API-DMAC7.html)
JP2019537599A5 (cg-RX-API-DMAC7.html)
JP2015532295A5 (cg-RX-API-DMAC7.html)
JP2005523922A5 (cg-RX-API-DMAC7.html)
JP2017537940A5 (cg-RX-API-DMAC7.html)
JP2010510237A5 (cg-RX-API-DMAC7.html)
JP2007520440A5 (cg-RX-API-DMAC7.html)
JP2009535307A5 (cg-RX-API-DMAC7.html)
JP2020532547A5 (cg-RX-API-DMAC7.html)
JP2020512337A5 (cg-RX-API-DMAC7.html)
JP2016518437A5 (cg-RX-API-DMAC7.html)
JP2010526146A5 (cg-RX-API-DMAC7.html)
JP2008505157A5 (cg-RX-API-DMAC7.html)
JP2004516314A5 (cg-RX-API-DMAC7.html)
JP2015505296A5 (cg-RX-API-DMAC7.html)
JP2005530811A5 (cg-RX-API-DMAC7.html)
JP2008505117A5 (cg-RX-API-DMAC7.html)
JP2007520452A5 (cg-RX-API-DMAC7.html)
JP2020128426A5 (cg-RX-API-DMAC7.html)
JP2020505354A5 (cg-RX-API-DMAC7.html)
JP2020511450A5 (cg-RX-API-DMAC7.html)
JP2019520344A5 (cg-RX-API-DMAC7.html)
JP2019519593A5 (cg-RX-API-DMAC7.html)
JP2020511536A5 (cg-RX-API-DMAC7.html)